Looks like 'shrooms might become a swanky and healthy thing to do! The fungi is affectionately called the Maitake mushroom, and literally means "dancing mushroom. Research has found it lowers blood pressure, abdominal obesity, and lipids in the blood.

Maitake Products plans to target the maitake (grifola frondosa) mushroom to treat metabolic syndrome. Metabolic syndrome is a common precondition for both coronary disease and type 2 diabetes. The condition is characterized by a group of metabolic risk factors including: abdominal obesity, atherogenic dyslipidemia, high blood pressure and insulin resistance. With the growing number of people affected by these conditions, Maitake claims there is significant market potential for its drug, SX-Fraction.

A preliminary clinical study was conducted among 19 patients with type 2 diabetes. Patients taking 9 tablets of SX-Fraction (per day) for 2 months found that it significantly reduced fasting blood glucose, triglycerides, and body weight. The possibility of maitake mushroom as a safe, natural agent for treatment of type 2 diabetes, Syndrome X and insulin resistance has been examined for the past several years and will soon prove to be a therapeutic dancing mushroom in days to come. Yeah man.

Suffering succotash - do you believe the nerve of these scientists professing the antithesis of insulin-dependent diabetes!! Scientist have proven that supplementation of Gymnema sylvestre appears to enhance endogenous insulin production by regeneration of the residual beta cells in insulin-dependent diabetes. Wouldn't this study imply that insulin-dependent diabetes is curable??

GS4, a water-soluble extract of the leaves of Gymnema sylvestre, was given to 27 patients with insulin-dependent diabetes on insulin therapy. They received 400 mg per day. Their insulin requirements came down together, along with their fasting blood glucose, HbA1c and glycosylated plasma protein levels. Patients in the study receiving insulin therapy only (without Gymnema sylvestre supplementation) showed no significant reduction in serum lipids, HbA1c or glycosylated plasma proteins when followed up after 10-12 months.

There you have it, folks. A study published in the Journal of Ethnopharmacologyin October 1990 says - there are possible ways to regenerate beta cells in insulin-dependent diabetics, previously believed to be nonexistent and gone forever. Never say never, right Dr. Faustman?

Much like a roadblock, but with a fortuitous outcome -- an experimental heart drug didn't achieve the primary goal of a late-stage trial but it did dramatically reduce the risk patients would develop diabetes.

The anti-oxidant, anti-inflammatory drug, the first of its kind, reduced the risk of developing diabetes by 64% and demonstrated a small but statistically significant reduction in blood sugar after 12 months. The study included data from 6,144-patients. The company believes this finding to be a serendipitous outcome, despite the initial shortcomings of the trial objective. They need to confirm it in a large clinical trial. The impressive diabetes results may come as a surprise to investors who have abandoned AtheroGenics or who have been betting the drug will fail.

Heart patients in the study received either 300 milligrams of the drug or a placebo on top of a host of standard-of-care medicines they were already taking, such as aspirin, cholesterol-lowering statins, blood thinners and/or diabetes medicines.

The drug had an undesirable impact on blood fats, raising bad LDL cholesterol by about 12% and lowering good HDL cholesterol by roughly the same amount. There were also some potentially troubling safety signals with a trend toward more heart failure in those taking the drug. In spite of the undesirable affects on blood lipids, the drug has a profound effect on diabetes. Further research will be conducted on the efficacy of this drug in reducing the risk of developing diabetes.

A Swedish study has found that elevated blood sugar in women is linked with increased risk of developing cancer.

Researchers identified 2,478 incident cases of cancer from records of 33,293 women and 31,304 men who participated in the study. Participants were recruited in the mid-1980s at age 40, 50 and 60 and the study covered a 13-year period. The records included levels of glucose in the blood when fasting and after receiving an infusion of glucose. Researchers calculated the cancer risk relative to blood glucose while adjusting for: age, year of enrollment, fasting time and smoking status. Women with blood sugar levels higher than normal have a total higher risk for cancer while for men the risk was unchanged at higher blood sugar levels. The overall risk of developing cancer for women in the top 25% of fasting blood glucose levels was 26% higher than those in the bottom 25%. Women with high fasting glucose levels had a higher risk of pancreatic, breast and endometrial cancers, while the increase in risk for malignant melanoma was two times higher.

While previous studies have shown that cancer risk for some cancers is higher for people with type 2 diabetes, this study suggests that something could be happening to trigger cancer much earlier, as glucose levels begin to rise. The scientists also found that the blood sugar levels gradually rose over the period of the study, which they suggest means that cancer risks would also continue to rise unless glucose levels were brought down by some means. The results were no different when they took Body Mass Index (BMI) into account.

The study provides further evidence for an association between abnormal glucose metabolism and cancer. If you ask me - I think this has to do with the pH levels of the blood. It is well known that cancer manifests in blood levels of higher acidity. Poor diabetic control can result in higher acid levels in the blood. The catch 22 is poor diabetic control leaves your entire blood chemistry off kilter and it cannot defend any rogue cells - especially those associated with malignant growth (i.e. cancer!)

Damage to the retina that sometimes comes with diabetes is associated with an increased risk of having a stroke.

A study involving 1,617 middle-aged people with diabetes led researchers to this conclusion, linking retinopathy and stroke risk. At the start of the study, 197 participants had moderate retinopathy and 44 had severe retinopathy. During an average follow-up of almost 8 years, 75 strokes occurred in the group as a whole. Considering all exacerbating factors -- such as blood pressure, insulin treatment and cholesterol levels -- having diabetic retinopathy more than doubled the likelihood of having a stroke.

Dr. Tien Y. Wong advised Reuters Health, "Diabetes can exert its effects on multiple organs in the body, and damage in the blood vessels seen in the eye -- retinopathy -- is a marker of probably unseen damage occurring elsewhere." Detecting blood vessel damage in the eye is linked to blood vessel damage in the brain, which could result in a stroke. He advises all eye care professionals to perform a more comprehensive assessment of stroke risk if they detect retinopathy in a patient.

A study published in the online edition of the journal Nature, found a sensor in the liver (LXR) activated by glucose that controls the body's metabolism of cholesterol and fat.

Scientists fed synthetic LXR to mice eating a diet of mostly simple sugars. They discovered that the mice metabolized glucose more effectively and that activation suppressed new production of glucose in the liver. That prompted the scientists to study glucose levels as the LXR activating mechanism in the liver. By controlling glucose sensing and fat synthesis by LXR, scientists may explain and correct why low-fat, high-carbohydrate diets can lead to an elevated level of triglycerides in the blood. LXR can sense surplus glucose, induce fatty acid synthesis, and prompt the liver's export of triglycerides into the bloodstream rather than being stored as fat.

LXR could resolve the problem of hyperglycemia and atherosclerosis by binding to glucose and cholesterol buildup in the body. LXR induced regression of atherosclerosis, the clogging, narrowing, and hardening of the body's large arteries and blood vessels that can lead to stroke, heart attack, and eye and kidney problems. Contrary to conventional wisdom, this experiment led to the discovery that glucose binds directly to LXR, representing the first signaling pathway of this kind.

In a joint statement, the American Diabetes Association (ADA) and American Heart Association (AHA) agree that lifestyle and medical interventions can help to prevent the development of heart disease in people with diabetes.

The clinical research journal Diabetes Care, outlines joint guidelines that encourage more aggressive prevention and treatment of the risk factors leading to heart disease, the number one killer of people with diabetes. Basic lifestyle changes include weight loss, CVD risk factors, increased physical activity, nutrition therapy, and weight control. In addition, the statement calls for increased medical interventions, such as the use of statins, ACE inhibitors, and other drugs to manage lipids, blood pressure, and blood glucose levels in people with diabetes. The recommendations apply equally to people with type 1 and type 2 diabetes.

These joint guidelines are part of a collaborative ongoing effort to strengthen efforts in the fight against cardiovascular disease, which affects two out of three people with diabetes. Once a person with diabetes has a heart attack or stroke, they do much worse than people without diabetes. Increase your chances of preventing an irreconcilable cardiovascular event. Good news for diabetics when it comes to diabetes and heart disease - at least one of them is preventable.